Free Biopharma Daily Stock Updates - 08/05/21

$XBI $125.54 +3.8%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$NVAX +5.5% Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination. source

$NVAX +5.5% Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine. source

$ENTA +8.9% Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19. source

Pipeline Updates

$APRE +2.6% Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs. source

$NBIX -0.6% Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease. source

$DRNA +1.7% Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria. source

$OCUL +3.1% Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases. source

$GILD +0.1% Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer. source

$PCVX +3.8% Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections. source

$EIGR +8.6% Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism. source

$EXEL +1.3% Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer. source

$IMRA +5.4% Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease. source

$SYRS +8.7% Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer. source

$CLNN +6.5% Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis. source

$VALN -1.9% Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate.source

$KPTI -24.2% Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results. source

$BYSI -18.4% BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type. source

$AMPE +19.8% Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update. source

$EDIT +18.45 Editas Medicine Announces Second Quarter 2021 Results and Business Updates. source

$SRPT +16.4% Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments. source

$AKBA +15.7% Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones. source

$LJPC +15.5% La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress. source

$SAVA +15.1% On 8/3 Cassava Sciences Reports Second Quarter 2021 Financial Results. source

$ARCT +20.5% On 8/3 Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study. source

Financial Updates

$CYDY -3.9% CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest. source

$SRRK +15.6% Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference. source

---

Posted by FS